Indeed, the combination of atezolizumab (anti-PDL1) and bevacizumab (anti-VEGF) is currently the first-line treatment for hepatocellular carcinoma [11,47], and new trials involving immune checkpoint inhibitors (anti-PD1/PD-L1 or anti-CTLA4) combined with molecularly targeted drugs are currently ongoing, producing promising preliminary results [48,49,50,51,52]. Here, CD274 is linked to hepatocellular carcinoma.